Realgar-Indigo Naturalis Formulation Combined with Anlotinib
2025PHD008-001
Approved small_molecule active
Quick answer
Realgar-Indigo Naturalis Formulation Combined with Anlotinib for Platinum-resistant Ovarian Cancer (PROC) is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Platinum-resistant Ovarian Cancer (PROC)
- Phase
- Approved
- Modality
- small_molecule
- Status
- active